Natera, Inc. (NTRA)
393.44
-11.35
(-2.80%)
USD |
NASDAQ |
Oct 16, 16:00
393.43
-0.01
(0.00%)
After-Hours: 20:00
Natera Research and Development Expense (Annual) : 624.11M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 624.11M |
| December 31, 2024 | 404.14M |
| December 31, 2023 | 318.00M |
| December 31, 2022 | 307.12M |
| December 31, 2021 | 228.60M |
| December 31, 2020 | 100.04M |
| December 31, 2019 | 51.36M |
| Date | Value |
|---|---|
| December 31, 2018 | 49.81M |
| December 31, 2017 | 50.06M |
| December 31, 2016 | 41.86M |
| December 31, 2015 | 27.71M |
| December 31, 2014 | 17.29M |
| December 31, 2013 | 11.55M |
| December 31, 2012 | 6.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Guardant Health, Inc. | 364.19M |
| Myriad Genetics, Inc. | 106.80M |
| CareDx, Inc. | 71.43M |
| Caris Life Sciences, Inc. | 101.58M |
| BioRestorative Therapies, Inc. | 10.09M |